Introduction
toxicities, B-cell malignancies
ADVERSE EVENTS
Bruton’s tyrosine kinase (BTK) is a member of the Tec family of non-receptor protein tyrosine kinases [Tirabrutinib (ONO-4059/GS-4059) is a second-generation, highly selective, covalent, irreversible oral inhibitor of BTK that was designed to avoid some limitations of first-generation BTK inhibitors, particularly “off-target” adverse events (AEs) and therapeutic resistance. Preclinical studies provided evidence regarding the cytostatic effects of tirabrutinib in vitro and in vivo [In clinical use, like other BTK inhibitors, the administration of tirabrutinib can be continued for as long as it shows clinical efficacy. However, some patients discontinue treatment with BTK inhibitors due to toxicities [Several Phase I and II clinical studies have been conducted in Japan in patients with relapsed or refractory B-cell malignancies [